Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
780 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01560416 | Fulvestrant With or Without Ganetespib in HR+ Breast Cancer | completed | Phase 2 | 50 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT06623097 | Exercise and Nutrition for Older Cancer Survivors and Their Support Person: The Vitality Study(VITALITY) | recruiting | N/A | 1,528 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT05358951 | Sleep Treatment Education Program for Young Adult Cancer Survivors (STEP-YA) | completed | N/A | 56 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT06523868 | Evaluation of Multi-Cancer Early Detection Testing in a High-Risk Military Population: The Sentinel Study | recruiting | N/A | 1,500 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT03974217 | Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts | active not recruiting | Phase 1 | 13 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT00378105 | Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple Myeloma | active not recruiting | Phase 1 / Phase 2 | 68 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT05528263 | Preventing Chemotherapy-Induced Peripheral Neuropathy With Acupuncture (PACT Trial)(PACT) | completed | N/A | 89 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT05740839 | High-Intensity Interval Exercise in Young Adult Survivors of Pediatric Brain Tumors: A Pilot Feasibility Study(HYPE) | recruiting | N/A | 30 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT06458049 | Sexual Health and Rehabilitation Online (SHAREonline) | active not recruiting | N/A | 84 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT06964958 | 177LuPSMA in Renal Cell Carcinoma(LASER) | active not recruiting | Phase 2 | 24 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT00548236 | The Active After Cancer Trial (AACT)(AACT) | active not recruiting | N/A | 120 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT03641755 | Olaparib + Sapacitabine in BRCA Mutant Breast Cancer | active not recruiting | Phase 1 | 10 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT03130439 | Abemaciclib for Patients With Retinoblastoma-Positive, Triple Negative Metastatic Breast Cancer | terminated | Phase 2 | 27 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT04421560 | Pembrolizumab, Ibrutinib and Rituximab in PCNSL | recruiting | Phase 1 / Phase 2 | 37 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT06475235 | Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL | recruiting | Phase 1 | 15 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT01853748 | T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial) | completed | Phase 2 | 512 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 19, 2026 | clinicaltrials |
| NCT04997096 | Exercise as a Preventive Agent to Combat Immobility in Patients With Ovarian or Endometrial Cancers Receiving Chemotherapy | recruiting | N/A | 30 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 19, 2026 | clinicaltrials |
| NCT05356117 | Resistance Exercise Combined With Protein Supplementation in People With Pancreatic Cancer: The RE-BUILD Trial | recruiting | N/A | 45 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 19, 2026 | clinicaltrials |
| NCT06138561 | Management of Cisplatin-Ineligible Patients With Metastatic Bladder Cancer and The Role of Geriatric Assessments | recruiting | — | 180 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT02158091 | A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL | active not recruiting | Phase 1 / Phase 2 | 32 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT03065062 | Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors | suspended | Phase 1 | 75 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT03580928 | Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL(AVO) | active not recruiting | Phase 2 | 72 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT03170206 | Study of Palbociclib in Combination With Binimetinib for Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer | completed | Phase 1 | 34 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT02909777 | Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma | completed | Phase 1 | 26 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT06283251 | PediRISE Feasibility | recruiting | N/A | 40 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT06831552 | Resource Intervention to Support Equity (RISE) in High-Risk Neuroblastoma(RISE in HR NBL) | recruiting | N/A | 84 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT04850846 | Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma | active not recruiting | Phase 2 | 60 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 9, 2026 | clinicaltrials |
| NCT05825469 | Development and Testing of Nutritional Algorithms (NACHO) | not yet recruiting | N/A | 130 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT01796197 | Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa | completed | Phase 2 | 23 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT07390643 | The DISCOVER Study(DISCOVERY) | not yet recruiting | N/A | 100 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT01468246 | The Young Women's Breast Cancer Study(HOHO) | active not recruiting | — | 1,302 | Dana-Farber Cancer InstituteOTHER | 2 | Feb 3, 2026 | clinicaltrials |
| NCT03070236 | PORTAL: Patient-reported Outcomes After Routine Treatment of Atypical Lesions | active not recruiting | N/A | 912 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 3, 2026 | clinicaltrials |
| NCT03485547 | Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | completed | Phase 1 | 5 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 2, 2026 | clinicaltrials |
| NCT05519982 | Sleep Treatment Education Program-1 (STEP-1) | completed | N/A | 70 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 2, 2026 | clinicaltrials |
| NCT05016947 | Venetoclax Plus Inotuzumab for B-ALL | active not recruiting | Phase 1 | 23 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT02919683 | Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral Cavity | active not recruiting | Phase 2 | 30 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT01494662 | HKI-272 for HER2-Positive Breast Cancer and Brain Metastases | completed | Phase 2 | 140 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT03289039 | Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer | terminated | Phase 2 | 21 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT05706766 | Prehabilitation Exercise Training in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation | recruiting | N/A | 30 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT05327452 | Testing Home-based Exercise Strategies in Underserved Minority Cancer Patients Undergoing Chemotherapy: the THRIVE Study | active not recruiting | N/A | 135 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT05524025 | The SPOT-HPV Study | completed | — | 360 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT06450171 | Evaluation of Multi-Cancer Early Detection Testing in a High-Risk Population: The INFORM Study | recruiting | N/A | 1,000 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT02441686 | Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma | completed | Phase 2 | 46 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT02950987 | Screening With Whole Body MRI For Detection Of Primary Tumors In Children And Adults With Li-Fraumeni Syndrome (LFS) And Other Cancer Predisposition Syndromes | active not recruiting | N/A | 150 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT04572763 | Copanlisib Plus Venetoclax in R/R DLBCL | active not recruiting | Phase 1 / Phase 2 | 48 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT04843904 | Safe Accelerated Venetoclax Escalation in CLL(SAVE) | active not recruiting | Phase 1 | 40 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT03912064 | A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT | active not recruiting | Phase 1 | 25 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 5, 2026 | clinicaltrials |
| NCT03929029 | Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced Melanoma | active not recruiting | Phase 1 | 11 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 5, 2026 | clinicaltrials |
| NCT04636710 | Refining Local-Regional Therapy for IBC | recruiting | N/A | 50 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 29, 2025 | clinicaltrials |
| NCT06038318 | Promoting Resilience in Early Survivorship Among Adolescents and Young Adults With Cancer | recruiting | N/A | 325 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 29, 2025 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials